Investors Purchase Large Volume of Call Options on Accelerate Diagnostics (AXDX)
Accelerate Diagnostics Inc (NASDAQ:AXDX) was the recipient of unusually large options trading on Monday. Stock traders acquired 3,074 call options on the company. This is an increase of approximately 713% compared to the typical volume of 378 call options.
Accelerate Diagnostics (NASDAQ:AXDX) traded up $0.35 during midday trading on Wednesday, hitting $23.25. The stock had a trading volume of 415,977 shares, compared to its average volume of 283,132. The company has a market capitalization of $1,290.00, a price-to-earnings ratio of -19.38 and a beta of 2.19. Accelerate Diagnostics has a 1 year low of $16.75 and a 1 year high of $30.45.
In other Accelerate Diagnostics news, Director Jack W. Schuler acquired 5,500 shares of the company’s stock in a transaction dated Friday, November 17th. The stock was purchased at an average price of $22.00 per share, with a total value of $121,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 50.00% of the company’s stock.
A number of research firms have recently weighed in on AXDX. ValuEngine lowered Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Friday, February 9th. BidaskClub lowered Accelerate Diagnostics from a “buy” rating to a “hold” rating in a research note on Tuesday. Zacks Investment Research lowered Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Monday, January 15th. Finally, BTIG Research lowered Accelerate Diagnostics from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 13th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $33.00.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.